 Scott Sagel
Concepts (385)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis | 90 | 2023 | 957 | 12.060 |
Why?
| | Aminophenols | 17 | 2022 | 112 | 3.650 |
Why?
| | Kartagener Syndrome | 20 | 2023 | 26 | 3.030 |
Why?
| | Ciliary Motility Disorders | 13 | 2023 | 21 | 2.980 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 26 | 2022 | 288 | 2.880 |
Why?
| | Quinolones | 15 | 2022 | 97 | 2.870 |
Why?
| | Sputum | 23 | 2023 | 290 | 2.820 |
Why?
| | Inflammation | 16 | 2023 | 2499 | 1.880 |
Why?
| | Lung | 22 | 2022 | 3672 | 1.760 |
Why?
| | Respiratory Function Tests | 20 | 2020 | 535 | 1.680 |
Why?
| | Respiratory System Agents | 3 | 2022 | 22 | 1.600 |
Why?
| | Biomarkers | 25 | 2022 | 3466 | 1.560 |
Why?
| | Benzodioxoles | 8 | 2022 | 83 | 1.500 |
Why?
| | Genetic Testing | 7 | 2021 | 382 | 1.480 |
Why?
| | Neonatal Screening | 5 | 2021 | 151 | 1.440 |
Why?
| | Aminopyridines | 6 | 2022 | 81 | 1.440 |
Why?
| | Lung Diseases | 6 | 2023 | 710 | 1.360 |
Why?
| | Bronchiectasis | 3 | 2023 | 108 | 1.330 |
Why?
| | Mycobacterium avium-intracellulare Infection | 3 | 2021 | 63 | 1.330 |
Why?
| | Pseudomonas Infections | 10 | 2023 | 188 | 1.290 |
Why?
| | Anti-Bacterial Agents | 13 | 2023 | 1484 | 1.230 |
Why?
| | Cilia | 16 | 2023 | 162 | 1.210 |
Why?
| | Chloride Channel Agonists | 10 | 2022 | 62 | 1.190 |
Why?
| | Anti-Inflammatory Agents | 4 | 2020 | 448 | 1.160 |
Why?
| | Mutation | 29 | 2022 | 3364 | 1.160 |
Why?
| | Azithromycin | 5 | 2023 | 80 | 1.160 |
Why?
| | Bronchoalveolar Lavage Fluid | 7 | 2019 | 608 | 1.110 |
Why?
| | Child | 65 | 2023 | 18488 | 1.090 |
Why?
| | Trypsinogen | 3 | 2021 | 9 | 1.080 |
Why?
| | Forced Expiratory Volume | 13 | 2021 | 516 | 0.950 |
Why?
| | Adolescent | 58 | 2023 | 17889 | 0.940 |
Why?
| | Vitamins | 2 | 2018 | 151 | 0.910 |
Why?
| | Pseudomonas aeruginosa | 11 | 2023 | 301 | 0.830 |
Why?
| | Antioxidants | 3 | 2018 | 533 | 0.820 |
Why?
| | Humans | 119 | 2023 | 115587 | 0.800 |
Why?
| | Algorithms | 4 | 2021 | 1490 | 0.790 |
Why?
| | Ethambutol | 1 | 2021 | 20 | 0.770 |
Why?
| | Young Adult | 37 | 2023 | 10470 | 0.750 |
Why?
| | Female | 77 | 2023 | 59913 | 0.740 |
Why?
| | Rifampin | 1 | 2021 | 68 | 0.740 |
Why?
| | Male | 74 | 2023 | 55949 | 0.730 |
Why?
| | Breath Tests | 5 | 2022 | 83 | 0.690 |
Why?
| | Disease Progression | 16 | 2020 | 2418 | 0.670 |
Why?
| | Mycobacterium avium Complex | 3 | 2021 | 92 | 0.660 |
Why?
| | Dietary Supplements | 3 | 2018 | 458 | 0.610 |
Why?
| | Malnutrition | 1 | 2018 | 62 | 0.600 |
Why?
| | C-Reactive Protein | 8 | 2022 | 364 | 0.580 |
Why?
| | Dyneins | 6 | 2023 | 29 | 0.570 |
Why?
| | Nontuberculous Mycobacteria | 3 | 2023 | 207 | 0.560 |
Why?
| | Drug Discovery | 1 | 2016 | 124 | 0.520 |
Why?
| | Leukocyte Elastase | 6 | 2023 | 79 | 0.510 |
Why?
| | Leukocyte L1 Antigen Complex | 5 | 2022 | 30 | 0.510 |
Why?
| | Prospective Studies | 23 | 2023 | 6264 | 0.500 |
Why?
| | Metabolomics | 1 | 2019 | 538 | 0.490 |
Why?
| | Mycobacterium Infections, Nontuberculous | 4 | 2023 | 337 | 0.480 |
Why?
| | Longitudinal Studies | 9 | 2022 | 2416 | 0.470 |
Why?
| | Nitric Oxide | 5 | 2019 | 832 | 0.460 |
Why?
| | Child, Preschool | 24 | 2023 | 9133 | 0.460 |
Why?
| | Automation | 1 | 2014 | 74 | 0.460 |
Why?
| | Infant, Newborn | 14 | 2022 | 5077 | 0.450 |
Why?
| | Granulocyte Colony-Stimulating Factor | 4 | 2022 | 70 | 0.450 |
Why?
| | Adult | 38 | 2022 | 30718 | 0.450 |
Why?
| | Exocrine Pancreatic Insufficiency | 2 | 2010 | 17 | 0.440 |
Why?
| | Clinical Trials as Topic | 5 | 2015 | 941 | 0.440 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2014 | 112 | 0.420 |
Why?
| | Microbiota | 5 | 2023 | 652 | 0.420 |
Why?
| | Respiratory System | 4 | 2019 | 141 | 0.410 |
Why?
| | Sweat | 4 | 2020 | 38 | 0.410 |
Why?
| | Otorhinolaryngologic Diseases | 1 | 2011 | 14 | 0.390 |
Why?
| | Sensitivity and Specificity | 7 | 2021 | 1718 | 0.380 |
Why?
| | Staphylococcal Infections | 3 | 2019 | 337 | 0.380 |
Why?
| | Tomography, X-Ray Computed | 6 | 2017 | 2392 | 0.380 |
Why?
| | Vitamin K Deficiency | 1 | 2010 | 10 | 0.370 |
Why?
| | Retrospective Studies | 17 | 2023 | 12608 | 0.370 |
Why?
| | Cytokines | 6 | 2023 | 1853 | 0.370 |
Why?
| | Vitamin A Deficiency | 1 | 2010 | 27 | 0.370 |
Why?
| | Cohort Studies | 13 | 2022 | 4944 | 0.360 |
Why?
| | Quality of Life | 4 | 2022 | 2385 | 0.360 |
Why?
| | Secretory Leukocyte Peptidase Inhibitor | 1 | 2009 | 6 | 0.340 |
Why?
| | Proteomics | 3 | 2022 | 859 | 0.340 |
Why?
| | Lactoferrin | 1 | 2009 | 28 | 0.330 |
Why?
| | Infant | 18 | 2023 | 7979 | 0.330 |
Why?
| | United States | 16 | 2021 | 12295 | 0.330 |
Why?
| | Bronchoscopy | 2 | 2008 | 245 | 0.330 |
Why?
| | Bronchitis | 1 | 2009 | 37 | 0.330 |
Why?
| | Muramidase | 1 | 2009 | 73 | 0.320 |
Why?
| | Vitamin D Deficiency | 1 | 2010 | 159 | 0.320 |
Why?
| | Tomography | 2 | 2018 | 21 | 0.310 |
Why?
| | Diverticulum | 1 | 2007 | 11 | 0.300 |
Why?
| | Tracheal Diseases | 1 | 2007 | 15 | 0.300 |
Why?
| | Administration, Oral | 3 | 2018 | 734 | 0.290 |
Why?
| | Tracheoesophageal Fistula | 1 | 2007 | 31 | 0.290 |
Why?
| | Data Interpretation, Statistical | 2 | 2021 | 324 | 0.290 |
Why?
| | Treatment Outcome | 12 | 2022 | 9159 | 0.280 |
Why?
| | Reproductive Health | 2 | 2017 | 70 | 0.280 |
Why?
| | Digestive System Surgical Procedures | 1 | 2007 | 89 | 0.280 |
Why?
| | Specimen Handling | 2 | 2020 | 156 | 0.280 |
Why?
| | Heterotaxy Syndrome | 2 | 2023 | 10 | 0.270 |
Why?
| | Bacteria | 5 | 2023 | 729 | 0.260 |
Why?
| | Severity of Illness Index | 7 | 2023 | 2578 | 0.260 |
Why?
| | Leukocyte Count | 5 | 2012 | 294 | 0.250 |
Why?
| | Age Factors | 5 | 2020 | 2907 | 0.240 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2005 | 117 | 0.240 |
Why?
| | Rhinitis | 2 | 2019 | 128 | 0.240 |
Why?
| | Genotype | 9 | 2023 | 1786 | 0.240 |
Why?
| | Chlorides | 3 | 2022 | 130 | 0.240 |
Why?
| | DNA, Bacterial | 4 | 2017 | 309 | 0.230 |
Why?
| | Probability | 3 | 2016 | 294 | 0.230 |
Why?
| | Situs Inversus | 1 | 2023 | 4 | 0.230 |
Why?
| | Oropharynx | 3 | 2015 | 36 | 0.230 |
Why?
| | Models, Neurological | 1 | 2006 | 213 | 0.230 |
Why?
| | Follow-Up Studies | 7 | 2018 | 4440 | 0.230 |
Why?
| | Neuronal Plasticity | 1 | 2006 | 214 | 0.230 |
Why?
| | Sinusitis | 2 | 2019 | 175 | 0.230 |
Why?
| | Proteins | 3 | 2015 | 920 | 0.220 |
Why?
| | Mucociliary Clearance | 2 | 2021 | 42 | 0.220 |
Why?
| | Drug Combinations | 5 | 2022 | 289 | 0.210 |
Why?
| | Metagenome | 3 | 2013 | 122 | 0.210 |
Why?
| | Body Mass Index | 5 | 2020 | 1971 | 0.210 |
Why?
| | Synapses | 1 | 2006 | 336 | 0.210 |
Why?
| | Monitoring, Immunologic | 1 | 2002 | 23 | 0.210 |
Why?
| | Respiration Disorders | 1 | 2023 | 68 | 0.210 |
Why?
| | Respiratory Tract Infections | 4 | 2015 | 323 | 0.210 |
Why?
| | Uteroglobin | 1 | 2022 | 16 | 0.210 |
Why?
| | Genetic Markers | 4 | 2016 | 325 | 0.210 |
Why?
| | Calreticulin | 1 | 2022 | 24 | 0.210 |
Why?
| | Prognosis | 5 | 2018 | 3339 | 0.210 |
Why?
| | HMGB Proteins | 1 | 2022 | 15 | 0.200 |
Why?
| | Chemistry, Clinical | 1 | 2002 | 11 | 0.200 |
Why?
| | Serum Amyloid A Protein | 2 | 2019 | 29 | 0.200 |
Why?
| | Peptide Hydrolases | 1 | 2023 | 109 | 0.200 |
Why?
| | Hydrogen | 1 | 2022 | 62 | 0.200 |
Why?
| | Aspergillosis, Allergic Bronchopulmonary | 1 | 2021 | 9 | 0.200 |
Why?
| | Interleukin-8 | 6 | 2012 | 241 | 0.200 |
Why?
| | Blood Glucose | 3 | 2023 | 1824 | 0.190 |
Why?
| | Antibiotics, Antitubercular | 1 | 2021 | 35 | 0.190 |
Why?
| | Cross-Over Studies | 2 | 2021 | 434 | 0.190 |
Why?
| | Desmosine | 2 | 2012 | 6 | 0.190 |
Why?
| | Disease Management | 3 | 2015 | 563 | 0.190 |
Why?
| | DNA Mutational Analysis | 5 | 2014 | 372 | 0.180 |
Why?
| | Leptin | 1 | 2022 | 211 | 0.180 |
Why?
| | Rhodospirillaceae | 1 | 2020 | 4 | 0.180 |
Why?
| | Glucose | 2 | 2023 | 904 | 0.180 |
Why?
| | Proteome | 2 | 2022 | 345 | 0.180 |
Why?
| | Mycobacterium abscessus | 1 | 2021 | 98 | 0.180 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2022 | 281 | 0.170 |
Why?
| | Cross-Sectional Studies | 7 | 2023 | 4435 | 0.170 |
Why?
| | Patient Acuity | 1 | 2019 | 42 | 0.170 |
Why?
| | Antitubercular Agents | 1 | 2021 | 170 | 0.170 |
Why?
| | Cytoskeletal Proteins | 3 | 2015 | 145 | 0.170 |
Why?
| | Alleles | 4 | 2017 | 794 | 0.170 |
Why?
| | Sleep Apnea, Central | 1 | 1999 | 8 | 0.170 |
Why?
| | Pneumonia | 2 | 2017 | 576 | 0.170 |
Why?
| | Autonomic Nervous System Diseases | 1 | 1999 | 27 | 0.170 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2018 | 691 | 0.160 |
Why?
| | Case-Control Studies | 6 | 2020 | 3022 | 0.160 |
Why?
| | Respiratory Tract Diseases | 1 | 2020 | 142 | 0.160 |
Why?
| | Oxidative Stress | 2 | 2018 | 1093 | 0.160 |
Why?
| | Hypoglycemia | 1 | 2023 | 386 | 0.160 |
Why?
| | Nutritional Status | 2 | 2018 | 289 | 0.160 |
Why?
| | Axonemal Dyneins | 3 | 2013 | 8 | 0.160 |
Why?
| | Diagnostic Techniques and Procedures | 1 | 2018 | 13 | 0.160 |
Why?
| | Saliva | 2 | 2015 | 189 | 0.160 |
Why?
| | Lipids | 1 | 2022 | 588 | 0.160 |
Why?
| | Air | 1 | 2018 | 35 | 0.160 |
Why?
| | Double-Blind Method | 3 | 2018 | 1660 | 0.150 |
Why?
| | Aptamers, Nucleotide | 1 | 2019 | 73 | 0.150 |
Why?
| | Neurons | 1 | 2006 | 1298 | 0.150 |
Why?
| | Reproductive Health Services | 1 | 2017 | 9 | 0.150 |
Why?
| | Neutrophils | 3 | 2015 | 1172 | 0.150 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2023 | 1137 | 0.150 |
Why?
| | Hirschsprung Disease | 1 | 1999 | 87 | 0.150 |
Why?
| | Respiration | 1 | 2018 | 177 | 0.150 |
Why?
| | Coinfection | 2 | 2020 | 120 | 0.150 |
Why?
| | Tobramycin | 2 | 2023 | 48 | 0.150 |
Why?
| | Health Services Misuse | 1 | 2017 | 36 | 0.140 |
Why?
| | Clofazimine | 1 | 2017 | 14 | 0.140 |
Why?
| | Middle Aged | 15 | 2021 | 26999 | 0.140 |
Why?
| | Body Height | 1 | 2017 | 180 | 0.140 |
Why?
| | Postoperative Complications | 1 | 2007 | 2161 | 0.140 |
Why?
| | Axoneme | 2 | 2013 | 7 | 0.140 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 192 | 0.140 |
Why?
| | Sexual Health | 1 | 2017 | 48 | 0.140 |
Why?
| | Immunologic Tests | 1 | 2016 | 16 | 0.140 |
Why?
| | Body Weight | 1 | 2020 | 867 | 0.130 |
Why?
| | Dried Blood Spot Testing | 1 | 2016 | 71 | 0.130 |
Why?
| | Zebrafish | 3 | 2013 | 412 | 0.130 |
Why?
| | Time Factors | 4 | 2018 | 6165 | 0.130 |
Why?
| | Prevalence | 2 | 2019 | 2264 | 0.130 |
Why?
| | Predictive Value of Tests | 3 | 2016 | 1805 | 0.130 |
Why?
| | Exome | 5 | 2014 | 202 | 0.130 |
Why?
| | Diagnostic Tests, Routine | 1 | 2016 | 88 | 0.130 |
Why?
| | Glucose Tolerance Test | 3 | 2023 | 344 | 0.130 |
Why?
| | Patient Selection | 1 | 2019 | 654 | 0.130 |
Why?
| | Gene Expression Profiling | 3 | 2018 | 1536 | 0.130 |
Why?
| | Molecular Targeted Therapy | 1 | 2018 | 348 | 0.130 |
Why?
| | Targeted Gene Repair | 1 | 2015 | 1 | 0.130 |
Why?
| | Insulin Resistance | 1 | 2023 | 1078 | 0.120 |
Why?
| | Microtubule-Associated Proteins | 2 | 2013 | 174 | 0.120 |
Why?
| | Pedigree | 5 | 2013 | 467 | 0.120 |
Why?
| | Hyperglycemia | 1 | 2018 | 294 | 0.120 |
Why?
| | Bacteria, Anaerobic | 2 | 2011 | 20 | 0.120 |
Why?
| | Nasal Mucosa | 4 | 2019 | 94 | 0.120 |
Why?
| | Venous Thromboembolism | 1 | 2017 | 234 | 0.120 |
Why?
| | Survival Rate | 2 | 2018 | 1650 | 0.110 |
Why?
| | Microscopy, Electron, Transmission | 4 | 2016 | 138 | 0.110 |
Why?
| | Ubiquinone | 2 | 2010 | 21 | 0.110 |
Why?
| | Intestine, Small | 1 | 2014 | 125 | 0.110 |
Why?
| | Homozygote | 3 | 2020 | 186 | 0.110 |
Why?
| | Sexual Behavior | 1 | 2017 | 440 | 0.110 |
Why?
| | Antigens, Surface | 1 | 2013 | 151 | 0.110 |
Why?
| | Vital Capacity | 1 | 2014 | 277 | 0.110 |
Why?
| | GTP-Binding Proteins | 1 | 2013 | 142 | 0.110 |
Why?
| | Phenotype | 6 | 2019 | 2829 | 0.110 |
Why?
| | Precision Medicine | 1 | 2016 | 344 | 0.100 |
Why?
| | Neutrophil Activation | 1 | 2013 | 94 | 0.100 |
Why?
| | Mycobacterium Infections | 1 | 2013 | 61 | 0.100 |
Why?
| | Models, Statistical | 1 | 2016 | 606 | 0.100 |
Why?
| | Proteolysis | 1 | 2012 | 145 | 0.100 |
Why?
| | DNA | 2 | 2018 | 1356 | 0.100 |
Why?
| | Elastin | 1 | 2012 | 78 | 0.100 |
Why?
| | Glycoproteins | 1 | 2013 | 309 | 0.100 |
Why?
| | Otitis Media with Effusion | 1 | 2011 | 21 | 0.100 |
Why?
| | Mycobacterium | 1 | 2013 | 103 | 0.100 |
Why?
| | Nasal Cavity | 1 | 2011 | 47 | 0.100 |
Why?
| | Turbinates | 1 | 2011 | 11 | 0.090 |
Why?
| | Tumor Suppressor Proteins | 1 | 2013 | 286 | 0.090 |
Why?
| | Polymerase Chain Reaction | 2 | 2011 | 1000 | 0.090 |
Why?
| | Dinoprost | 1 | 2010 | 31 | 0.090 |
Why?
| | Biomarkers, Pharmacological | 1 | 2010 | 26 | 0.090 |
Why?
| | Metagenomics | 2 | 2021 | 131 | 0.090 |
Why?
| | Practice Guidelines as Topic | 1 | 2018 | 1405 | 0.090 |
Why?
| | Inflammation Mediators | 2 | 2005 | 479 | 0.090 |
Why?
| | Leukocytes, Mononuclear | 1 | 2013 | 501 | 0.090 |
Why?
| | Biopsy | 4 | 2015 | 1056 | 0.090 |
Why?
| | Interprofessional Relations | 1 | 2012 | 258 | 0.090 |
Why?
| | Diabetes Mellitus | 1 | 2018 | 906 | 0.090 |
Why?
| | Microbial Sensitivity Tests | 2 | 2021 | 299 | 0.090 |
Why?
| | Chronic Disease | 2 | 2015 | 1598 | 0.090 |
Why?
| | Membrane Potentials | 2 | 2010 | 251 | 0.080 |
Why?
| | Lung Injury | 1 | 2012 | 199 | 0.080 |
Why?
| | Morbidity | 2 | 2018 | 278 | 0.080 |
Why?
| | Pseudomonas | 2 | 2022 | 27 | 0.080 |
Why?
| | Exotoxins | 1 | 2008 | 14 | 0.080 |
Why?
| | Heterozygote | 1 | 2009 | 252 | 0.080 |
Why?
| | Confidence Intervals | 1 | 2009 | 309 | 0.080 |
Why?
| | Spirometry | 3 | 2015 | 253 | 0.080 |
Why?
| | Administration, Inhalation | 2 | 2023 | 644 | 0.080 |
Why?
| | Electric Impedance | 2 | 2018 | 99 | 0.080 |
Why?
| | Peroxidase | 2 | 2022 | 157 | 0.070 |
Why?
| | Otorhinolaryngologic Surgical Procedures | 1 | 2007 | 33 | 0.070 |
Why?
| | RNA Precursors | 1 | 2008 | 136 | 0.070 |
Why?
| | Pregnancy Rate | 2 | 2017 | 55 | 0.070 |
Why?
| | Evidence-Based Medicine | 1 | 2011 | 684 | 0.070 |
Why?
| | DNA-Binding Proteins | 1 | 2014 | 1316 | 0.070 |
Why?
| | Genomics | 2 | 2021 | 645 | 0.070 |
Why?
| | Sequence Analysis, DNA | 3 | 2015 | 732 | 0.070 |
Why?
| | Biomedical Research | 1 | 2012 | 588 | 0.070 |
Why?
| | Reproducibility of Results | 3 | 2010 | 2800 | 0.070 |
Why?
| | Diagnostic Errors | 1 | 2007 | 151 | 0.070 |
Why?
| | Genetic Predisposition to Disease | 2 | 2018 | 2125 | 0.070 |
Why?
| | RNA, Messenger | 1 | 2013 | 2574 | 0.070 |
Why?
| | Needs Assessment | 2 | 2017 | 318 | 0.060 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2005 | 23 | 0.060 |
Why?
| | Colorado | 2 | 2018 | 4113 | 0.060 |
Why?
| | Staphylococcus aureus | 1 | 2008 | 385 | 0.060 |
Why?
| | Hospitalization | 2 | 2014 | 1765 | 0.060 |
Why?
| | Exercise Tolerance | 1 | 2006 | 223 | 0.060 |
Why?
| | Reference Values | 2 | 2017 | 744 | 0.060 |
Why?
| | Vasodilator Agents | 1 | 2006 | 308 | 0.060 |
Why?
| | Diabetic Retinopathy | 1 | 2006 | 149 | 0.060 |
Why?
| | Microscopy, Electron | 2 | 2015 | 409 | 0.060 |
Why?
| | Piperazines | 1 | 2006 | 314 | 0.060 |
Why?
| | Linear Models | 2 | 2017 | 776 | 0.060 |
Why?
| | Immunity, Innate | 1 | 2009 | 731 | 0.060 |
Why?
| | Glucagon | 1 | 2023 | 93 | 0.050 |
Why?
| | Pancreatic Elastase | 1 | 2022 | 67 | 0.050 |
Why?
| | Down Syndrome | 1 | 2007 | 336 | 0.050 |
Why?
| | Pregnancy | 3 | 2017 | 5548 | 0.050 |
Why?
| | Constipation | 1 | 2022 | 75 | 0.050 |
Why?
| | Aspergillus fumigatus | 1 | 2021 | 20 | 0.050 |
Why?
| | Pyrrolidines | 1 | 2022 | 56 | 0.050 |
Why?
| | Computer Simulation | 1 | 2006 | 881 | 0.050 |
Why?
| | Nucleotides | 1 | 2022 | 113 | 0.050 |
Why?
| | Cough | 1 | 2001 | 107 | 0.050 |
Why?
| | Observational Studies as Topic | 1 | 2021 | 89 | 0.050 |
Why?
| | Symptom Flare Up | 1 | 2020 | 40 | 0.050 |
Why?
| | Mutant Proteins | 1 | 2020 | 96 | 0.050 |
Why?
| | Indoles | 1 | 2022 | 309 | 0.040 |
Why?
| | Asthma | 2 | 2013 | 2066 | 0.040 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2017 | 1198 | 0.040 |
Why?
| | Pyrazoles | 1 | 2022 | 362 | 0.040 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2023 | 500 | 0.040 |
Why?
| | Pilot Projects | 2 | 2017 | 1377 | 0.040 |
Why?
| | Pyridines | 1 | 2022 | 425 | 0.040 |
Why?
| | British Columbia | 1 | 2018 | 18 | 0.040 |
Why?
| | Fatal Outcome | 1 | 1999 | 286 | 0.040 |
Why?
| | Length of Stay | 1 | 2022 | 958 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 930 | 0.040 |
Why?
| | Hospitals | 1 | 2022 | 585 | 0.040 |
Why?
| | Ultrasonography, Prenatal | 1 | 1999 | 235 | 0.040 |
Why?
| | Early Medical Intervention | 1 | 2018 | 51 | 0.040 |
Why?
| | Age Distribution | 1 | 2017 | 341 | 0.040 |
Why?
| | Ontario | 1 | 2016 | 108 | 0.030 |
Why?
| | Radiography, Thoracic | 1 | 2017 | 165 | 0.030 |
Why?
| | Respiratory Therapy | 1 | 2015 | 20 | 0.030 |
Why?
| | Microscopy, Video | 1 | 2015 | 26 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2017 | 4665 | 0.030 |
Why?
| | Respiratory Syncytial Virus Vaccines | 1 | 2015 | 24 | 0.030 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 2016 | 102 | 0.030 |
Why?
| | Risk Factors | 2 | 2019 | 8697 | 0.030 |
Why?
| | Radiography | 1 | 2017 | 826 | 0.030 |
Why?
| | Regression Analysis | 1 | 2017 | 959 | 0.030 |
Why?
| | Hypertension, Pulmonary | 1 | 2006 | 1749 | 0.030 |
Why?
| | Enterobacteriaceae | 1 | 2015 | 33 | 0.030 |
Why?
| | North America | 1 | 2015 | 261 | 0.030 |
Why?
| | Sex Factors | 1 | 2020 | 1736 | 0.030 |
Why?
| | Enterobacteriaceae Infections | 1 | 2015 | 33 | 0.030 |
Why?
| | Staphylococcus | 1 | 2015 | 69 | 0.030 |
Why?
| | Counseling | 1 | 2017 | 347 | 0.030 |
Why?
| | Genetic Therapy | 1 | 2016 | 260 | 0.030 |
Why?
| | Societies, Medical | 1 | 2018 | 684 | 0.030 |
Why?
| | Pneumococcal Vaccines | 1 | 2015 | 132 | 0.030 |
Why?
| | Genotyping Techniques | 1 | 2014 | 70 | 0.030 |
Why?
| | Planarians | 1 | 2013 | 1 | 0.030 |
Why?
| | Chlamydomonas | 1 | 2013 | 2 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1440 | 0.030 |
Why?
| | Canada | 1 | 2015 | 335 | 0.030 |
Why?
| | Insulin | 1 | 2023 | 2082 | 0.030 |
Why?
| | Open Reading Frames | 1 | 2013 | 116 | 0.030 |
Why?
| | Xenopus laevis | 1 | 2013 | 118 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2014 | 515 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2017 | 1870 | 0.030 |
Why?
| | Cytoplasm | 1 | 2013 | 255 | 0.030 |
Why?
| | Genes, Recessive | 1 | 2012 | 72 | 0.030 |
Why?
| | Computer Communication Networks | 1 | 2012 | 32 | 0.030 |
Why?
| | Placebos | 1 | 2012 | 198 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 317 | 0.030 |
Why?
| | Superoxides | 1 | 2013 | 215 | 0.030 |
Why?
| | Genetic Association Studies | 1 | 2014 | 343 | 0.030 |
Why?
| | Fluorescent Antibody Technique | 1 | 2013 | 398 | 0.030 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2012 | 155 | 0.030 |
Why?
| | Airway Remodeling | 1 | 2012 | 60 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2012 | 339 | 0.020 |
Why?
| | DNA Barcoding, Taxonomic | 1 | 2011 | 17 | 0.020 |
Why?
| | Logistic Models | 1 | 2016 | 1856 | 0.020 |
Why?
| | Incidence | 1 | 2017 | 2335 | 0.020 |
Why?
| | Biota | 1 | 2011 | 35 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2013 | 804 | 0.020 |
Why?
| | Biofilms | 1 | 2013 | 222 | 0.020 |
Why?
| | Influenza Vaccines | 1 | 2015 | 498 | 0.020 |
Why?
| | Autoantigens | 1 | 2013 | 398 | 0.020 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2013 | 443 | 0.020 |
Why?
| | Ion Channels | 1 | 2010 | 123 | 0.020 |
Why?
| | Cell Cycle Proteins | 1 | 2013 | 553 | 0.020 |
Why?
| | Registries | 1 | 2017 | 1770 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2012 | 677 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2011 | 621 | 0.020 |
Why?
| | Animals | 3 | 2013 | 32102 | 0.020 |
Why?
| | Genes, rRNA | 1 | 2007 | 39 | 0.020 |
Why?
| | Protein Binding | 1 | 2013 | 1917 | 0.020 |
Why?
| | Mexico | 1 | 2008 | 163 | 0.020 |
Why?
| | Epithelial Cells | 1 | 2013 | 961 | 0.020 |
Why?
| | gamma-Tocopherol | 1 | 2007 | 4 | 0.020 |
Why?
| | beta Carotene | 1 | 2007 | 18 | 0.020 |
Why?
| | Micelles | 1 | 2007 | 34 | 0.020 |
Why?
| | Genes, Bacterial | 1 | 2007 | 156 | 0.020 |
Why?
| | Aged | 2 | 2017 | 19251 | 0.020 |
Why?
| | Biological Availability | 1 | 2007 | 119 | 0.020 |
Why?
| | Leukocytes | 1 | 2008 | 281 | 0.020 |
Why?
| | ROC Curve | 1 | 2008 | 451 | 0.020 |
Why?
| | Research Design | 1 | 2012 | 946 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2008 | 746 | 0.020 |
Why?
| | Sildenafil Citrate | 1 | 2006 | 58 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2017 | 6417 | 0.020 |
Why?
| | Acute Disease | 1 | 2008 | 914 | 0.020 |
Why?
| | Sulfones | 1 | 2006 | 98 | 0.020 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2013 | 1098 | 0.020 |
Why?
| | Rats | 1 | 2013 | 5034 | 0.020 |
Why?
| | Purines | 1 | 2006 | 159 | 0.020 |
Why?
| | Genetic Carrier Screening | 1 | 2004 | 24 | 0.020 |
Why?
| | Infant Care | 1 | 2004 | 43 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2013 | 2353 | 0.010 |
Why?
| | Infant Nutritional Physiological Phenomena | 1 | 2004 | 133 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2007 | 2790 | 0.010 |
Why?
|
|
Sagel's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|